BridgeBio Pharma Operating Income 2018-2024 | BBIO

BridgeBio Pharma annual/quarterly operating income history and growth rate from 2018 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • BridgeBio Pharma operating income for the quarter ending September 30, 2024 was $-0.192B, a 21.6% increase year-over-year.
  • BridgeBio Pharma operating income for the twelve months ending September 30, 2024 was $-0.544B, a 2.65% decline year-over-year.
  • BridgeBio Pharma annual operating income for 2023 was $-0.607B, a 18.58% increase from 2022.
  • BridgeBio Pharma annual operating income for 2022 was $-0.512B, a 11.17% decline from 2021.
  • BridgeBio Pharma annual operating income for 2021 was $-0.577B, a 21.53% increase from 2020.
BridgeBio Pharma Annual Operating Income
(Millions of US $)
2023 $-607
2022 $-512
2021 $-577
2020 $-474
2019 $-266
2018 $-184
2017 $-44
BridgeBio Pharma Quarterly Operating Income
(Millions of US $)
2024-09-30 $-192
2024-06-30 $-176
2024-03-31 $0
2023-12-31 $-177
2023-09-30 $-158
2023-06-30 $-146
2023-03-31 $-126
2022-12-31 $-129
2022-09-30 $-129
2022-06-30 $-80
2022-03-31 $-174
2021-12-31 $-166
2021-09-30 $-149
2021-06-30 $-94
2021-03-31 $-168
2020-12-31 $-127
2020-09-30 $-120
2020-06-30 $-125
2020-03-31 $-102
2019-12-31 $-79
2019-09-30 $-55
2019-06-30 $-69
2019-03-31 $-64
2018-12-31
2018-09-30 $-41
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $6.773B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $24.935B 8.18
Dr Reddy's Laboratories (RDY) India $12.596B 24.10
Bausch Health Cos (BHC) Canada $2.792B 2.06
Supernus Pharmaceuticals (SUPN) United States $2.108B 28.70
Amphastar Pharmaceuticals (AMPH) United States $1.738B 10.44
Personalis (PSNL) United States $0.396B 0.00
Taysha Gene Therapies (TSHA) United States $0.314B 21.86
Assembly Biosciences (ASMB) United States $0.095B 0.00
Sol-Gel Technologies (SLGL) Israel $0.025B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00